Free tool
FAERS Monitor: Follistim Aq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021211 or its brand name (Follistim Aq, Follitropin Alfa/Beta). Reports on generic versions are filed under their own applications.
Reports
1,143
Serious
148
13% of reports
Hospitalization
65
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event176
- headache118
- poor quality device used91
- abdominal distension80
- product packaging quantity issue74
- product quality issue69
- fatigue66
- incorrect dose administered66
- injection site pain62
- nausea61
- product dose omission issue54
- circumstance or information capable of leading to medication error51
- device malfunction43
- ovarian hyperstimulation syndrome43
- maternal exposure during pregnancy32
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 4 |
| 2008 | 4 |
| 2010 | 5 |
| 2011 | 11 |
| 2012 | 4 |
| 2013 | 19 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 15 |
| 2017 | 27 |
| 2018 | 63 |
| 2019 | 217 |
| 2020 | 144 |
| 2021 | 208 |
| 2022 | 144 |
| 2023 | 20 |
| 2024 | 18 |
| 2025 | 21 |
| 2026 | 205 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,016 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 43 | 345.9 | 257.2 | 14,179 |
| poor quality device usedSignal | 91 | 168.4 | 138.2 | 14,849 |
| product packaging quantity issueSignal | 74 | 121.3 | 97.2 | 8,656 |
| circumstance or information capable of leading to medication errorSignal | 51 | 27.8 | 21.3 | 1,292 |
| no adverse eventSignal | 176 | 17.9 | 15.6 | 2,811 |
| abdominal distensionSignal | 80 | 14.1 | 11.4 | 966 |
| device malfunctionSignal | 43 | 11.3 | 8.4 | 393 |
| product quality issueSignal | 69 | 9.4 | 7.4 | 509 |
| maternal exposure during pregnancySignal | 32 | 6.6 | 4.7 | 147 |
| incorrect dose administeredSignal | 66 | 5.3 | 4.2 | 230 |
| injection site painSignal | 62 | 3.7 | 2.9 | 122 |
| headacheSignal | 118 | 3.5 | 2.9 | 211 |
| product dose omission issueSignal | 54 | 3.4 | 2.6 | 89 |
| fatigue | 66 | 1.6 | 1.2 | 13 |
| nausea | 61 | 1.4 | 1.1 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.